Javascript must be enabled to continue!
A pilot study on metabolomic characterization of human glioblastomas and patient plasma
View through CrossRef
Abstract
Purpose
To determine whether recurrent GBMs are metabolically distinct from primary GBM, and whether patient plasma can be used as a liquid biopsy to reflect this difference.
Methods
In a single center cohort study, tissue and blood samples from 15 patients with glioblastoma (9 glioblastoma tissues at diagnosis, 3 pairs of tissue, and 6 pairs of plasma specimens at diagnosis and at recurrence) were analyzed.
Results
Several metabolites had significant alternations in both tumor and plasma specimens. In the tissue, the following representative metabolites had a significant increase in peak intensity at recurrence compared to diagnosis: N-alpha-methylhistamine (p = 0.037), glycerol-3-phosphate (p = 0.029), phosphocholine (p = 0.045), and succinic acid (p = 0.025). In patient plasma, metabolites that significantly increased at recurrence included: 2,4-difluorotoluene (p = 0.031), diatrizoic acid (p = 0.032), indole-3-acetate with (p = 0.029), urea (P = 0.025), pseudouridine (p = 0.042), and maltose (p = 0.035). Metabolites that significantly decreased in plasma at recurrence were: eicosenoic acid (p = 0.017), glucose-1-phosphate (p = 0.017), FA 18:2 (linoleic acid) (p = 0.017), arginine (p = 0.036), fatty acids 20:3 (homo-gamma-linolenic acid (p = 0.036), galactosamine (p = 0.007), and FA 18:3 (linolenic acid) (P = 0.012). Principal component analysis showed that the metabolomic profiles differ between tumor tissue and patient plasma.
Conclusions
Our data suggest that metabolomic profiles of human GBM tissue and patient plasma differ at diagnosis and at recurrence. Many metabolites involved in tumorigenesis and metabolomic flexibility were identified. A larger study using targeted metabolomic assay is warranted to measure the levels of these metabolites, which will help identify the metabolomic signatures in both GBM tissue and patient plasma for risk stratification, clinical outcome prediction, and development of new adjuvant metabolomic-targeting therapy.
Research Square Platform LLC
Title: A pilot study on metabolomic characterization of human glioblastomas and patient plasma
Description:
Abstract
Purpose
To determine whether recurrent GBMs are metabolically distinct from primary GBM, and whether patient plasma can be used as a liquid biopsy to reflect this difference.
Methods
In a single center cohort study, tissue and blood samples from 15 patients with glioblastoma (9 glioblastoma tissues at diagnosis, 3 pairs of tissue, and 6 pairs of plasma specimens at diagnosis and at recurrence) were analyzed.
Results
Several metabolites had significant alternations in both tumor and plasma specimens.
In the tissue, the following representative metabolites had a significant increase in peak intensity at recurrence compared to diagnosis: N-alpha-methylhistamine (p = 0.
037), glycerol-3-phosphate (p = 0.
029), phosphocholine (p = 0.
045), and succinic acid (p = 0.
025).
In patient plasma, metabolites that significantly increased at recurrence included: 2,4-difluorotoluene (p = 0.
031), diatrizoic acid (p = 0.
032), indole-3-acetate with (p = 0.
029), urea (P = 0.
025), pseudouridine (p = 0.
042), and maltose (p = 0.
035).
Metabolites that significantly decreased in plasma at recurrence were: eicosenoic acid (p = 0.
017), glucose-1-phosphate (p = 0.
017), FA 18:2 (linoleic acid) (p = 0.
017), arginine (p = 0.
036), fatty acids 20:3 (homo-gamma-linolenic acid (p = 0.
036), galactosamine (p = 0.
007), and FA 18:3 (linolenic acid) (P = 0.
012).
Principal component analysis showed that the metabolomic profiles differ between tumor tissue and patient plasma.
Conclusions
Our data suggest that metabolomic profiles of human GBM tissue and patient plasma differ at diagnosis and at recurrence.
Many metabolites involved in tumorigenesis and metabolomic flexibility were identified.
A larger study using targeted metabolomic assay is warranted to measure the levels of these metabolites, which will help identify the metabolomic signatures in both GBM tissue and patient plasma for risk stratification, clinical outcome prediction, and development of new adjuvant metabolomic-targeting therapy.
Related Results
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash
Abstract
This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Laboratory Model Study of Single Five-Spot and Single Injection Well Pilot Waterflooding
Laboratory Model Study of Single Five-Spot and Single Injection Well Pilot Waterflooding
Abstract
Many full-scale waterflooding operations are preceded by pilot floods, one purpose of which is to provide an estimate of recoverable oil. A laboratory mo...
Magnetohydrodynamics enhanced radio blackout mitigation system for spacecraft during planetary entries
Magnetohydrodynamics enhanced radio blackout mitigation system for spacecraft during planetary entries
(English) Spacecraft entering planetary atmospheres are enveloped by a plasma layer with high levels of ionization, caused by the extreme temperatures in the shock layer. The charg...
Metabolomic characterization of human glioblastomas and patient plasma: a pilot study
Metabolomic characterization of human glioblastomas and patient plasma: a pilot study
Background Glioblastoma (GBM) is a clinically challenging primary brain tumor with poor survival outcome despite surgical resection and intensive chemoradiation. The metabolic hete...
Metabolomic characterization of human glioblastomas and patient plasma: a pilot study
Metabolomic characterization of human glioblastomas and patient plasma: a pilot study
Background Glioblastoma (GBM) is a clinically challenging primary brain tumor with poor survival outcome despite surgical resection and intensive chemoradiation. The metabolic hete...
Characterization of Glioblastoma by Contrast-Enhanced Flair Sequences
Characterization of Glioblastoma by Contrast-Enhanced Flair Sequences
The tissues placed on the edge of a glioblastoma's necrotic cavities are more vascularized than other pseudocystic central nervous system (CNS) tumours, both benign and malignant. ...
Differentiating brain metastasis from glioblastoma by time-dependent diffusion MRI
Differentiating brain metastasis from glioblastoma by time-dependent diffusion MRI
Abstract
Background
This study was designed to investigate the use of time-dependent diffusion magnetic resonance imaging (MRI) parameters in distin...
Abstract 2164: Overexpression of the TERT binding proteins GABPA/B in Glioblastoma
Abstract 2164: Overexpression of the TERT binding proteins GABPA/B in Glioblastoma
Abstract
Enhanced expression of TERT in gliomas is a result of two hotspot mutations, C228T and C250T, at the promoter region. GA-binding proteins selectively bind a...

